Mesar

Olmesartan medoxomil, the active ingredient in Mesar, is a angiotensin II receptor blocker presented as a tablet for oral use. It lowers elevated blood pressure in adults with primary hypertension. GNH USA supplies Mesar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan medoxomil is an angiotensin II receptor blocker used to manage high blood pressure conditions. - Hypertension: reduces systolic and diastolic blood pressure in patients with primary hypertension, helping to lower cardiovascular risk. - Hypertensive heart disease: assists in controlling blood pressure to prevent progression of cardiac complications. - Stroke prevention: contributes to reducing the risk of stroke associated with uncontrolled hypertension.

Olmesartan medoxomil may cause a range of adverse reactions.

Common Side Effects: - Dizziness: light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling unusually tired. - Diarrhoea: loose stools. - Upper respiratory tract infection: nasopharyngitis. - Hyperkalaemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue or throat. - Severe hypotension: markedly low blood pressure. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: abnormal liver enzymes or hepatitis. - Neutropenia: low neutrophil count increasing infection risk. - Myocardial infarction: rare reports of heart attack.

Before initiating therapy with Olmesartan medoxomil, certain precautions should be observed. - Renal function monitoring: assess serum creatinine and eGFR periodically. - Electrolyte assessment: check potassium levels to avoid hyperkalaemia. - Concomitant diuretics: adjust dose if using potassium‑sparing diuretics. - Hepatic impairment: use with caution in patients with severe liver disease. - Pregnancy: avoid use during pregnancy due to potential fetal toxicity. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use may increase risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - ACE inhibitors: concurrent use raises the risk of angioedema.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: can increase lithium levels, risking toxicity. - Cyclosporine: may elevate serum creatinine. - Diuretics: may enhance hypotensive effect, requiring dose adjustment.